July 2021 tender notification
Pharmac is pleased to provide the latest tender results.
Correction to June 2021 tender notification
Pharmac incorrectly notified a Principal Supply Status award in the Community and Hospital in June 2021 for mometasone furoate.
Corrections and amendments are in bold and strikethrough below.
Download the tender notification [PDF 48 KB]
Tender results
PHARMAC has resolved to award tenders for Principal Supply Status for some products included in the 2020/21 Invitation to Tender, dated 2 November 2020.
Some of the pharmaceuticals that will be delisted when the period of Principal Supply Status commences may be subject to existing listing contracts with PHARMAC. Suppliers of pharmaceuticals that are subject to such contracts should continue to supply their pharmaceuticals under those contracts. PHARMAC will continue to subsidise those pharmaceuticals accordingly until such time as those pharmaceuticals are delisted.
Notification of Product Changes (NOPC) forms, Containered Trade Product Pack (CTPP) codes and Pharmacodes
Please note that for any changes (price change, pack size change, new listing etc) to be effective in the Pharmaceutical Schedule (including Section H), suppliers are required to submit a Notification of Product Changes (NOPC) form to PHARMAC, the Pharmacy Guild and the NZULM by:
- For new listings, by 4pm on 12 August 2021 or the 5th of the month prior to listing, whichever is earlier
- For price changes, by 4pm on the 12th of the month prior to the date of subsidy change
PHARMAC cannot list a product (and pharmacies cannot claim) without this information.
More information about this process and NOPC forms can be found on our website.
Suppliers are required to ensure that a Pharmacode has been obtained from the Pharmacy Guild of New Zealand(external link) and that a CTPP code has been obtained from the New Zealand Universal List of Medicines(external link).
Pharmacodes and CTPP codes must be provided to PHARMAC by the 5th of the month prior to the date of listing, or 10 business days following the market notification date (whichever is earliest).
PHARMAC cannot list a product (and pharmacies cannot claim) without the correct Pharmacode.
2020/21 Tender – Principal Supply Status applies until 30 June 2024
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
1. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
Date of subsidy change |
Principal Supply date |
|---|---|---|---|---|---|---|
|
Mometasone furoate |
Crm 0.1%; 15 g OP tube |
$1.51 |
$1.95 |
Elocon Alcohol Free |
1 September 2021 |
1 February 2022 |
|
Mometasone furoate |
Crm 0.1%; 50 g OP tube |
$2.50 |
$3.10 |
Elocon Alcohol Free |
1 September 2021 |
1 February 2022 |
|
Mometasone furoate1 |
Lotn 0.1%; 30 ml OP bottle |
$6.30 |
$4.50 |
Elocon |
1 September 2021 |
1 February 2022 |
|
Mometasone furoate |
Oint 0.1%; 15 g OP tube |
$1.51 |
$1.95 |
Elocon |
1 September 2021 |
1 February 2022 |
|
Mometasone furoate1 |
Oint 0.1%; 50 g OP tube |
$2.90 |
$2.90 |
Elocon |
1 September 2021 |
1 February 2022 |
|
1This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 5, clause 3.1 (b)(ii) of the 2020/21 Invitation To Tender. |
||||||
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
2. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand (Supplier) |
DV Limit |
Listing date |
Principal Supply Status date |
|---|---|---|---|---|---|---|---|
|
Mometasone furoate |
Crm 0.1%; 15 g OP tube |
$1.51 |
$1.95 |
Elocon Alcohol Free |
5% |
1 September 2021 |
1 February 2022 |
|
Mometasone furoate |
Crm 0.1%; 50 g OP tube |
$2.50 |
$3.10 |
Elocon Alcohol Free |
5% |
1 September 2021 |
1 February 2022 |
|
Mometasone furoate2 |
Lotn 0.1%; 30 ml OP bottle |
$6.30 |
$4.50 |
Elocon |
5% |
1 September 2021 |
1 February 2022 |
|
Mometasone furoate |
Oint 0.1%; 15 g OP tube |
$1.51 |
$1.95 |
Elocon |
5% |
1 September 2021 |
1 February 2022 |
|
Mometasone furoate2 |
Oint 0.1%; 50 g OP tube |
$2.90 |
$2.90 |
Elocon |
5% |
1 September 2021 |
1 February 2022 |
|
2This product will be supplied at the Price from the 1st day of the month prior to the listing date, as per Schedule 6, clause 3.1 (b)(ii) of the 2020/21 Invitation To Tender. |
|||||||
2020/21 Tender – Principal Supply Status applies until 30 June 2024
Community pharmaceutical tenders – Section B of the Pharmaceutical Schedule
See table 4 below for changes to Section B of the Pharmaceutical Schedule in relation to fluorouracil.
Hospital pharmaceutical tenders – Section H of the Pharmaceutical Schedule
3. Tenders awarded to currently listed pharmaceuticals where no other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current |
New |
Principal Supply brand |
DV Limit |
Listing date |
Principal Supply date |
|---|---|---|---|---|---|---|---|
|
Flumazenil |
Inj 0.1 mg per ml, 5 ml ampoule; 10 ampoule pack |
$132.68 |
$110.12 |
Hameln (Max Health) |
5% |
1 September 2021 |
1 February 2022 |
4. Tenders awarded to pharmaceuticals where at least one other brand is listed.
The decisions were as follows:
|
Chemical name |
Presentation; |
Current pack price |
New pack price |
Principal Supply brand (Supplier) |
DV Limit |
Listing date |
Principal Supply Status date |
Brand (Supplier) affected by delisting |
|---|---|---|---|---|---|---|---|---|
|
Fluorouracil1 |
Inj 50 mg per ml, 20 ml vial; 1 vial pack |
$12.00 |
$10.51 |
Fluorouracil Accord (Accord) |
5% |
1 September 2021 |
1 February 2022 |
Fluorouracil Ebewe (Sandoz) |
|
Fluorouracil1 |
Inj 50 mg per ml, 100 ml vial; 1 vial pack |
$30.00 |
$29.44 |
Fluorouracil Accord (Accord) |
5% |
1 September 2021 |
1 February 2022 |
Fluorouracil Ebewe (Sandoz) |
|
1The price and subsidy of Fluorouracil (PCT only – Specialist) in Section B of the Pharmaceutical Schedule will also be amended to the above prices from 1 September 2021. The subsidy of fluorouracil (Baxter) inj 1 mg for ECP in Section B of the Pharmaceutical Schedule will also be amended from $0.66 per 1 mg to $0.62 per 1 mg from 1 September 2021. |
||||||||
For products included in the 2018/19, 2019/20 and 2020/21 Invitation to Tender where no announcement has yet been made, either a decision is still pending or is provisional, subject to the product gaining market approval and being available to supply, and subject to Pharmac Board (or its delegate) approval. We will keep you informed of any updates regarding such tender products as decisions are made. If you have any queries regarding this notification, please contact Pharmac on 0800 66 00 50.